HK Stock MarketDetailed Quotes

02256 ABBISKO-B

Watchlist
  • 4.340
  • -0.070-1.59%
Not Open Dec 20 16:08 CST
2.95BMarket Cap-166.92P/E (TTM)

About ABBISKO-B Company

We are an R&D-driven clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. Since inception, we have built a strong internal R&D engine, supported by our excellent discovery team and multi-dimensional discovery platform. With strong discovery capabilities, we have strategically designed and developed more than 10 oncology-focused projects, including five in the clinical phase. We aim to be a leading biopharmaceutical company to discover and develop novel and differentiated therapies in cancer and beyond to meet the critical unmet needs of patients in China and around the world. We strategically focus on small-molecule precision oncology therapy, small-molecule immuno-oncology therapy and their combination therapies. With their good efficacy and safety, we believe this is the development trend and next generation solution for cancer treatment.

Company Profile

Symbol02256
Company NameABBISKO-B
ISINKYG0028A1085
Listing DateOct 13, 2021
Issue Price12.46
Shares Offered140.74M share(s)
FoundedMar 28, 2018
Registered AddressCayman Islands
Chairmanyaochang xu
Secretaryyanhuayuhongping chen
Audit InstitutionErnst & Young
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeP.O. Box 309 Ugland House Grand Cayman KY1-1104 Cayman Islands
Head Office and Principal Place of Business40th Floor, Dah Sing Finance Centre, 248 Queen's Road East, Wan Chai, Hong Kong
Fiscal Year Ends12-31
Employees275
MarketHong Kong motherboard
Phone(86021)68912098
EmailPublic@abbisko.com;Bd@abbisko.com
Websitehttp://www.abbisko.com
Business Heyu Cayman Co., Ltd. is a Chinese clinical-stage biopharmaceutical company. The company is dedicated to discovering and developing innovative and differentiated small molecule oncology therapies. The company has two core candidate products ABSK011 and ABSK091 and 12 other pipeline candidate products. ABSK011 is a potent and highly selective small molecule fibroblast growth factor receptor 4 (FGFR4) inhibitor. ABSK091 is a molecular targeted candidate and is an efficient and selective inhibitor of FGFR subtypes 1, 2, and 3. The company's products are mainly used to treat hepatocellular carcinoma (HCC), urothelial cancer (UC), and gastric cancer (GC).

Company Executives

  • Name
  • Position
  • Salary
  • yaochang xu
  • Chairman of the Board, CEOs, Executive Director, Chairman of the Nomination Committee, Remuneration Committee Members, Authorized Representative
  • --
  • hongping yu
  • Executive Director, Senior Vice President of Medicinal Chemistry, Chief Scientific Officer, Joint Company Secretary
  • --
  • chui chen
  • Executive Director, Senior Vice President of Biology, Chief Scientific Officer
  • --
  • yanmin tang
  • Non-executive Directors
  • --
  • piaoyang sun
  • Independent Non-Executive Director, Nomination Committee Members, Audit Committee Members
  • --
  • hongbin sun
  • Independent Non-Executive Director, Chairman of the Audit Committee, Remuneration Committee Members, Nomination Committee Members
  • --
  • lei wang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Audit Committee Members
  • --
  • jing ji
  • Chief Medical Officer
  • --
  • zidong zhang
  • Chief Financial Officer
  • --
  • zhen zhang
  • VP, Head of Chemistry, Manufacturing and Control (CMC)
  • --
  • yanhua chen
  • Joint Company Secretary, Authorized Representative
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-0.05%